Neuralstem Plans Deep Dive Into Failed Phase II Major Depression Trial
Failure of NSI-189 in major depression study sends stock price down about 50% and next steps for development are unclear.
You may also be interested in...
Neuralstem is moving forward with development of its spinal cord-derived stem cell treatment for patients with amyotrophic lateral sclerosis (ALS) following mostly positive Phase II results for the product.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.